Research Article

Shock Wave Therapy Enhances Mitochondrial Delivery into Target Cells and Protects against Acute Respiratory Distress Syndrome

Kun-Chen Lin,1 Christopher Glenn Wallace,2 Tsung-Cheng Yin,3,4 Pei-Hsun Sung,4,5 Kuan-Hung Chen,1 Hung-I Lu,6 Han-Tan Chai,5 Chih-Hung Chen,7 Yi-Ling Chen,5,8 Yi-Chen Li,9 Pei-Lin Shao,9 Mel S. Lee,3 Jiunn-Jye Sheu,6,8 and Hon-Kan Yip4,5,8,9,10

1Department of Anesthesiology, Kaohsiung Chang Gung Memorial Hospital and Chang Gung University College of Medicine, Kaohsiung 83301, Taiwan
2Department of Plastic Surgery, University Hospital of South Manchester, Manchester, UK
3Department of Orthopaedic Surgery, Kaohsiung Chang Gung Memorial Hospital and Chang Gung University College of Medicine, Kaohsiung 83301, Taiwan
4Center for Shockwave Medicine and Tissue Engineering, Kaohsiung Chang Gung Memorial Hospital, Kaohsiung 83301, Taiwan
5Division of Cardiology, Department of Internal Medicine, Kaohsiung Chang Gung Memorial Hospital and Chang Gung University College of Medicine, Kaohsiung 83301, Taiwan
6Division of Thoracic and Cardiovascular Surgery, Department of Surgery, Kaohsiung Chang Gung Memorial Hospital and Chang Gung University College of Medicine, Kaohsiung 83301, Taiwan
7Divisions of General Medicine, Department of Internal Medicine, Kaohsiung Chang Gung Memorial Hospital and Chang Gung University College of Medicine, Kaohsiung 83301, Taiwan
8Institute for Translational Research in Biomedicine, Kaohsiung Chang Gung Memorial Hospital, Kaohsiung 83301, Taiwan
9Department of Nursing, Asia University, 500 Lioufeng Rd., Wufeng, Taichung 41354, Taiwan
10Department of Medical Research, China Medical University Hospital, China Medical University, Taichung 40402, Taiwan

Correspondence should be addressed to Jiunn-Jye Sheu; cvsjjs@gmail.com and Hon-Kan Yip; han.gung@msa.hinet.net

Received 19 March 2018; Accepted 5 August 2018; Published 21 October 2018

Academic Editor: Fabio S Lira

Copyright © 2018 Kun-Chen Lin et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

This study tested the hypothesis that shock wave therapy (SW) enhances mitochondrial uptake into the lung epithelial and parenchymal cells to attenuate lung injury from acute respiratory distress syndrome (ARDS). ARDS was induced in rats through continuous inhalation of 100% oxygen for 48 h, while SW entailed application 0.15 mJ/mm² for 200 impulses at 6 Hz per left/right lung field. In vitro and ex vivo studies showed that SW enhances mitochondrial uptake into lung epithelial and parenchyma cells (all \( p < 0.001 \)). Flow cytometry demonstrated that albumin levels and numbers of inflammatory cells (Ly6G+/CD14+/CD68+/CD11b/c+) in bronchoalveolar lavage fluid were the highest in untreated ARDS, were progressively reduced across SW, Mito, and SW + Mito (all \( p < 0.0001 \)), and were the lowest in sham controls. The same profile was also seen for fibrosis/collagen deposition, levels of biomarkers of oxidative stress (NOX-1/NOX-2/oxidized protein), inflammation (MMP-9/TNF-α/NF-κB/IL-1β/ICAM-1), apoptosis (cleaved caspase 3/PARP), fibrosis (Smad3/TGF-β), mitochondrial damage (cytosolic cytochrome c) (all \( p < 0.0001 \)), and DNA damage (γ-H2AX+), and numbers of parenchymal inflammatory cells (CD11+/CD14+/CD40L+/F4/80+) (\( p < 0.0001 \)). These results suggest that SW-assisted Mito therapy effectively protects the lung parenchyma from ARDS-induced injury.
1. Introduction

The respiratory system (i.e., oral-nasal-laryngeal tract, bronchus, trachea, and alveolar sacs in the lungs) is critical for maintenance of an adequate oxygen supply and excretion of carbon dioxide (CO2). For this purpose, the lung parenchyma has a dense capillary network mediating gaseous exchange. The lung is vulnerable to damage from a variety of causes, including viruses, bacteria, toxic chemicals/smoke, food aspiration, septic or cardiacogenic shock, resuscitation after circulatory arrest, alveolar-type pulmonary edema, massive blood transfusion, and ischemia-reperfusion injury after bypass surgery or organ transplantation [1–9]. Moreover, sustained insults may ultimately develop into clinical acute respiratory distress syndrome (ARDS) [9–11]. Despite pharmacologic advances and continuous renewal of management strategies [12–16], in-hospital mortality from ARDS remains unacceptably high [9, 10, 17–19]. Consequently, there is an urgent need for a safe and efficacious alternative treatment for this high-risk group of patients.

The mechanisms underlying acute lung injury/ARDS are multifactorial and include inflammation, alveolar leukocytosis, protein leakage, mitochondrial-free radical production, mitochondrial damage/loss, generation of reactive oxygen species (ROS) and resultant lung oxidant stress, and apoptosis [4, 9, 20–24]. Within this context, we hypothesize that a treatment that could reverse mitochondrial loss may, in turn, inhibit ROS-free radical generation and improve ARDS parameters. Previous studies by others [25–27] and ourselves [28–30] have shown that mitochondrial transfection effectively protects against acute organ damage, including sepsis-induced acute lung injury [13, 25], acute ischemia-reperfusion injury of the heart [27], liver [26, 28], and lung [30], and monocrotaline-induced pulmonary arterial hypertension [29]. Additionally, shock wave (SW) therapy entailing delivery of a series of transient pressure waves characterized by a high peak pressure (100 MPa), fast pressure rise (<10 ns), rapid propagation, and short life cycle (10 μs) produced by an appropriate generator reportedly reverses ischemia-related organ dysfunction, mainly by enhancing angiogenesis, recruiting endothelial progenitor cells, and suppressing inflammation and oxidative stress [31–33]. In the present study, therefore, we used a rat model to test the hypothesis that SW-assisted mitochondrial therapy would be superior to either therapy alone for protection of the lung against ARDS injury.

2. Materials and Methods

2.1. Ethics. All animal experimental procedures were approved by the Institute of Animal Care and Use Committee at Kaohsiung Chang Gung Memorial Hospital (Affidavit of Approval of Animal Use Protocol number 2016032205) and performed in accordance with the Guide for the Care and Use of Laboratory Animals (The Eighth Edition of the Guide for the Care and Use of Laboratory Animals (NRC 2011)).

Animals were housed in an Association for Assessment and Accreditation of Laboratory Animal Care International (AAALAC-) approved animal facility in our hospital with controlled temperature and light cycle (24°C and 12/12 light cycle).

2.2. Inducing ARDS in SD Rats. The ARDS model used in this study has been described in our recent studies [30, 34], wherein pure oxygen (i.e., 100% O2) was continuously administered to the rat for 48 h. In detail, a close system of glass (i.e., for monitoring the safety of each animal) square box was created. Inside the close system, the adequate food and water were provided for the animals. At least five animals were accommodated for each time in the glass box. Oxygen cannulation was firmly connected to the glass box with an oxygen meter to monitor the oxygen gas supply in the box to achieve each animal exposure to 100% oxygen for 48 hours.

2.3. Animal Grouping and Application of SW. Pathogen-free, adult male Sprague-Dawley (SD) rats (n = 30) weighing 325–350 g (Charles River Technology, BioLASCO, Taiwan Co. Ltd., Taiwan) were randomized into five groups (n = 6 in each group): group 1, sham controls (intravenous injection of 0.5 ml of normal saline); group 2, ARDS; group 3, ARDS + SW (0.15 mJ/mm2 for 200 impulses at 6 Hz per left/right lung field applied once 3 h after completing 48 h of oxygen inhalation); group 4, ARDS + mitochondria (Mito) (2000 μg/rat administered intravenously with a time interval identical to SW therapy); and group 5, ARDS + SW + Mito. Animals were sacrificed on day 5 after ARDS induction.

All animals were anesthetized (inhaled 2.0% isoflurane) in a supine position on a warming pad at 37°C during the application of SW to the left and then right lungs. To avoid affecting the heart during SW, the focus type of SW (Storz Duolith SD1, STORZ MEDICAL AG, Switzerland) was utilized. In addition, mitochondrial oxygen consumption rates were determined using a Mito stress test kit (i.e., Seahorse Bioscience, Billerica, MA) and the XF24 Analyzer.

2.4. Mitochondrial Isolation from Donors and MitoTracker Staining for Mitochondria. Liver mitochondria were isolated from donor SD rats as previously described [35]. The rats were fasted overnight prior to the mitochondrial isolation procedure, then sacrificed, and their gallbladders and livers were carefully removed. Immediately, the liver (3 g) was immersed in 50 ml of ice-cold 1Bc (10 mM Tris-MOPS, 5 mM EGTA/Tris, 200 mM sucrose, and pH 7.4) in a beaker, followed by rinsing the liver free of blood with ice-cold 1Bc. The liver was then minced with scissors in a beaker surrounded by ice. 1Bc was discarded during mincing and replaced with 18 ml of ice-cold fresh 1Bc. The liver was then homogenized with a Teflon pestle. The homogenates were transferred to a 50 ml polypropylene Falcon tube and centrifuged at 600 g for 10 minutes at 4°C. The supernatants were transferred to fresh tubes for centrifugation at 7000 g for 10 minutes at 4°C. The supernatants were discarded, and the pellets were washed with 5 ml ice-cold 1Bc. Again, the supernatants from the pellets were centrifuged at 7000 g for 10 minutes at 4°C. The supernatants were discarded, and the pellets containing the mitochondria were resuspended. The concentration of the mitochondrial suspensions was
measured using the Biuret method. Each 10 mg of isolated mitochondria was labeled with 1 M of MitoTracker Red CMXRos (Invitrogen, Carlsbad, CA) through incubation at 37°C for 30 minutes. Mitochondrial transfection was performed for the study animals immediately after labeling (i.e., <3 hrs after the isolation procedure).

2.5. Procedure and Protocol for Quantification of Oxygen Consumption Rate (OCR) of Isolated Mitochondria (Seahorse Method) (Figure 1). The procedure and protocol have also been described in our recent report [30]. In detail, functional activity of isolated mitochondria from rat liver was determined with an Extracellular Flux Analyzer (XF24, Seahorse Bioscience, MA, USA) by assessing the degree of coupling between the electron transport chain (ETC) and the oxidative phosphorylation machinery (OXPHOS). Bioenergetics of mitochondria as reflected in the integrity of electron transport chain and capacity of oxidative phosphorylation were evaluated by measuring the mitochondrial oxygen consumption rate (OCR). In this study, isolated mitochondria (10 μg/well) from rat liver were diluted in cold 1X mitochondrial assay solution (MAS) (70 mM sucrose, 220 mM mannitol, 10 mM KH2PO4, 5 mM MgCl2, 2 mM HEPES, 1.0 mM EGTA, and pH 7.2), followed by spinning down at 3000 g for 30 minutes. After attachment of mitochondria to XF24 plate, coupling reaction was initiated with the administration of substrate (10.0 mM succinate). State 3 was initiated with ADP (0.5 mM), while state 4 was induced by the administration of substrate (10.0 mM succinate). State 3/4 transition was performed for the study animals immediately after labeling. OCR of mitochondria in reactions mentioned above was sequentially measured.

2.6. In Vitro Study for Determining the Impact of SW on Enhancing Mitochondrial Transfusion in the Rat Lung Epithelial Cells (LEC). To elucidate whether SW therapy could enhance mitochondrial transfusion into the rat lung epithelial cells (LEC), the LECs were cultured in F-12K medium (i.e., 10% FBS + 1% Penicillin-Streptomycin (Gibco) in 1 x 10⁶ cells) in T25 flask for 24 h, followed by with and without SW treatment (0.2 ml/mm² for 100 shots). The cells (3 x 10⁵) were then cultured in EZ slide. 24 h after the cell culturing, 50 μg of exogenous mitochondria was transfused into the cultured cells (3 x 10⁵). 90 minutes later after transfection, the endogenous mitochondria in these cells were stained by MitoTracker Green (Invitrogen M7514, 1:100 nM). Additionally, these cells were also stained by MitoTracker Orange (Invitrogen M7510, 1:500 nM).

2.7. Pathological Assessment of Lung Injury. The procedure and protocol have been described in our previous reports [23, 24, 30, 35]. In detail, lung specimens were sectioned at 5 μm for light microscopy and H&E staining was performed to investigate the number of alveolar sacs in a blinded fashion [23, 24, 30, 35]. Three lung sections from each rat were analyzed. For quantification, three randomly selected high-power fields (HPFs; 200x) were examined in each section. The mean number per HPF for each animal was then determined by a summation of all numbers divided by 9. The extent of crowded area, which was defined as the region of thickened septa in lung parenchyma associated with partial or complete collapse of alveoli on H&E-stained sections, was also performed in a blinded fashion. The following scoring system [23, 24] was adopted: 0 = no detectable crowded area; 1 = <15% of crowded area; 2 = 15–25% of crowded area; 3 = 25–50% of crowded area; 4 = 50–75% of crowded area; 5 = >75%–100% of crowded area/HPF.

2.8. Bronchoalveolar Lavage and Lung Specimen Preparation. To elucidate the impact of SW mitochondrial treatment on protecting the lung from ARDS injury, bronchoalveolar lavage (BAL) was performed and the BAL fluid was collected for study in six additional rats from each group.

2.9. Immunofluorescent (IF) Studies. The procedures and protocols for IF examination were also based on our recent study [23, 24, 30, 35]. Briefly, for IF staining, rehydrated paraffin sections were first treated with 3% H2O2 for 30 minutes and incubated with Immuno-Block reagent (BioSB, Santa Barbara, CA, USA) for 30 minutes at room temperature. Sections were then incubated with primary antibodies specifically against CD14 (1:50, Santa Cruz), CD11 (1:500, Abcam), F4/80 (1:100, Santa Cruz), CD40L (1:100, Abcam), and γ-H2AX (1:1000, Abcam) while sections incubated with irrelevant antibodies served as controls. Three kidney sections from each rat were analyzed. For quantification, three randomly selected HPFs (400x for IF) were analyzed in each section. The mean number of positively stained cells per HPF for each animal was then determined by the summation of all numbers divided by 9.

2.10. Western Blot Analysis. The procedure and protocol for Western blot analysis have been described in our previous reports [23, 24, 30, 35]. Briefly, equal amounts (50 μg) of protein extract were loaded and separated by SDS-PAGE using acrylamide gels. After electrophoresis, the separated proteins were transferred electrophoretically to a polyvinylidene difluoride (PVDF) membrane (Amersham Biosciences, Amersham, UK). Nonspecific sites were blocked by incubation of the membrane in blocking buffer (5% nonfat dry milk in T-TBS (TBS containing 0.05% Tween 20)) overnight. The membranes were incubated with the indicated primary antibodies (matrix metalloproteinase- (MMP-) 9 (1:3000, Abcam, ab76003, Cambridge, MA, USA), tumor necrosis factor- (TNF-) α (1:1000, Cell Signaling, number 3707), Danvers, MA, USA), nuclear factor- (NF-) κB p65 (1:600, Abcam, ab16502, Cambridge, MA, USA), NADPH oxidase-(NOX-) 1 (1:1500, Sigma, SAB4200097, St. Louis, Mo, USA), NOX-2 (1:750, Sigma, SAB4200118, St. Louis, Mo, USA), interleukin- (IL-) 1β (1:1000, Cell Signaling, number 12426, Danvers, MA, USA), intercellular adhesion molecule- (ICAM-) 1 (1:1000, Abcam, ab2213, Cambridge, MA, USA), caspase 3 (1:1000, Cell Signaling, number 9665, Danvers, MA, USA), cleaved poly (ADP-ribose) polymerase (c-PARP) (1:1000, Cell Signaling, number 9542), transforming growth factor- (TGF-) β (1:500, Abcam, ab64715), phosphorylated-(p-) Smad3 (1:1000, Cell Signaling, number 9520), cytosolic...
cytochrome c (1:1000, BD, 556433, Franklin, NJ, USA),
mitochondrial cytochrome c (1:1000, BD, 556433, Franklin, NJ, USA), and actin (1:10000, Millipore, number MAB1501, 
Billerica, MA, USA)) for 1 hour at room temperature. Horse-
radish peroxidase-conjugated anti-rabbit immunoglobulin 
IgG (1:2000, Cell Signaling, number 7074, Danvers, MA,
USA) was used as a secondary antibody for a one-hour incubation at room temperature. The washing procedure was repeated eight times within one hour. Immunoreactive bands were visualized by enhanced chemiluminescence (ECL; Amersham Biosciences, Amersham, UK) and exposed to Biomax film (Kodak, Rochester, NY, USA). For quantification, ECL signals were digitized using Labwork software (UVP, Waltham, MA, USA).

2.11. Assessment of Oxidative Stress. The procedure and protocol for assessing the protein expression of oxidative stress have been detailed in our previous reports [23, 24, 30, 35]. The Oxyblot Oxidized Protein Detection Kit was purchased from Chemicon, Billerica, MA, USA (S7150). DNPH derivatization was carried out on 6 μg of protein for 15 minutes according to the manufacturer’s instructions. One-dimensional electrophoresis was carried out on 12% SDS-polyacrylamide gel after DNPH derivatization. Proteins were transferred to nitrocellulose membranes which were then incubated in the primary antibody solution (anti-DNP 1 : 150) for 2 hours, followed by incubation in secondary antibody solution (1 : 300) for 1 hour at room temperature. The washing procedure was repeated eight times within 40 minutes. Immunoreactive bands were visualized by enhanced chemiluminescence (ECL; Amersham Biosciences, Amersham, UK) which was then exposed to Biomax film (Kodak, Rochester, NY, USA). For quantification, ECL signals were digitized using Labwork software (UVP, Waltham, MA, USA). For Oxyblot protein analysis, a standard control was loaded on each gel.

2.12. Histopathological Assessment in Lung Parenchyma. To analyze the integrity of collagen synthesis and deposition, three lung paraffin sections (4 μm) were stained with Picrosirius red (1% Sirius red in saturated picric acid solution) for one hour at room temperature using standard methods.
Figure 3: Inflammatory mediators and leakage of albumin in bronchoalveolar lavage (BAL) fluid by day 5 after ARDS induction. (a) Flow cytometric analysis of numbers of Ly6G+ cells in BAL, *versus other groups with different symbols (†, ‡, §, ¶), \( p < 0.0001 \). (b) Flow cytometric analysis of numbers of CD14+ cells in BAL, *versus other groups with different symbols (†, ‡, §, ¶), \( p < 0.0001 \). (c) Flow cytometric analysis of numbers of CD68+ cells in BAL, *versus other groups with different symbols (†, ‡, §, ¶), \( p < 0.0001 \). (d) Flow cytometric analysis of numbers of CD11b/c+ cells in BAL, *versus other groups with different symbols (†, ‡, §, ¶), \( p < 0.0001 \). (e) Protein expression of albumin level in BAL, *versus other groups with different symbols (†, ‡, §, ¶), \( p < 0.0001 \). All statistical analyses were performed by one-way ANOVA, followed by Bonferroni multiple comparison post hoc test (\( n = 6 \) for each group). Symbols (*, †, ‡, §) indicate significance (at 0.05 level). SC = sham control; ARDS = acute respiratory distress syndrome; Mito = mitochondria; SW = shock wave.
The sections were then washed twice with 0.5% acetic acid. The water was physically removed from the slides by vigorous shaking. After dehydration in 100% ethanol thrice, the sections were cleaned with xylene and mounted in a resinous medium. Ten low-power fields (10x) of each section were used to identify Sirius red-positive area on each section. The integrated area ($\mu$m$^2$) of condensed collagen deposition in each section was calculated using Image Tool 3 (IT3) image analysis software (University of Texas, Health Science Center, San Antonio (UTHSCSA); Image Tool for Windows, Version 3.0, USA). Three selected sections were quantified for each animal. Three randomly selected HPFs (100x) were analyzed in each section. After determining the number of pixels in each collagen deposition area per HPF, the numbers of pixels obtained from the three HPFs were summed. The procedure was repeated in two other sections for each animal. The mean pixel number per HPF for each animal was then determined by summing all pixel numbers and divided by 9. The mean integrated area ($\mu$m$^2$) of collagen deposition area in lung parenchyma per HPF was obtained using a conversion factor of 19.24 (1 $\mu$m$^2$ corresponded to 19.24 pixels).

To elucidate the fibrosis of lung parenchyma, Masson's trichrome stain was performed according to the manufacturer's instruction. The analytical method for identification of fibrotic area was identical to the method for analysis of condensed collagen deposition area.

2.13. Statistical Analysis. Quantitative data are expressed as means $\pm$ SD. Statistical analysis was adequately performed by ANOVA followed by Bonferroni multiple comparison post hoc test. Statistical analysis was performed using SPSS statistical software for Windows version 22 (SPSS for Windows, version 22; SPSS, IL, USA). A value of $p < 0.05$ was considered as statistically significant.

3. Results

3.1. SW Therapy Enhances Exogenous Mitochondrial Transfusion into Lung Epithelial Cells. In vitro observations revealed that SW therapy significantly enhanced transfusion of exogenous mitochondria into rat lung epithelial cells as compared to transfusion alone (Figure 1). In vivo, numbers
Figure 5: CD11+ and CD14+ cell infiltration in lung parenchyma by day 5 after ARDS induction. (a to e) Immunofluorescent (IF) microscopic finding (400x) for identification of CD11+ cells (green color) in lung parenchyma. Red color indicated exogenous mitochondria. (f) Analytical result of number of CD11+ cells, * versus other groups with different symbols (†, ‡, §, ¶), p < 0.0001. (g to k) IF microscopic finding (400x) for identification of CD14+ cells (green color) in lung parenchyma. Red color indicated exogenous mitochondria. Analytical result of number of CD14+ cells, * versus other groups with different symbols (†, ‡, §, ¶), p < 0.0001. The scale bars in the right lower corner represent 20 μm. All statistical analyses were performed by one-way ANOVA, followed by Bonferroni multiple comparison post hoc test. Symbols (*, †, ‡, §, ¶) indicate significance (at 0.05 level). SC = sham control; ARDS = acute respiratory distress syndrome; Mito = mitochondria; SW = shock wave.
Figure 6: F4/80+ and CD40L+ cell infiltration in lung parenchyma by day 5 after ARDS induction. (a to e) Immunofluorescent (IF) microscopic finding (400x) for identification of F4/80+ cells (green color) in lung parenchyma. Red color indicated exogenous mitochondria. (f) Analytical result of number of F4/80+ cells, * versus other groups with different symbols (†, ‡, §, ¶), p < 0.0001. (g to k) IF microscopic finding (400x) for identification of CD40L+ cells (green color) in lung parenchyma. Red color indicated exogenous mitochondria. (l) Analytical result of number of CD40L+ cells, * versus other groups with different symbols (†, ‡, §, ¶), p < 0.0001. The scale bars in the right lower corner represent 20 μm. All statistical analyses were performed by one-way ANOVA, followed by Bonferroni multiple comparison post hoc test. Symbols (*, †, ‡, §, ¶) indicate significance (at 0.05 level). SC = sham control; ARDS = acute respiratory distress syndrome; Mito = mitochondria; SW = shock wave.
of mitochondria in the lung parenchyma of ARDS rats treated with SW plus mitochondrial transfusion (SW + Mito) were significantly higher than those in the lungs of untreated ARDS animals or ARDS animals treated with Mito alone (Figure 2). Measurement of the mitochondrial oxygen consumption rate showed that mitochondrial activity was satisfactory for purposes of the present study (Figure 2).

3.2. Flow Cytometric Analysis of Inflammatory Mediators and Albumin Leakage in Bronchoalveolar Lavage (BAL) Fluid. Flow cytometric analysis demonstrated that the numbers of Ly6G+, CD14+, CD68+, and CD11b/c+ inflammatory cells were highest in BAL fluid from untreated ARDS rats, were significantly and progressively lower across the ARDS + SW, ARDS + Mito, and ARDS + SW + Mito groups, and were the lowest in the sham control (SC) group (Figure 3). In addition, Western blot analysis showed that the profile of albumin levels in BAL fluid, an indicator of increased lung permeability and exudate leakage related to lung parenchymal damage in ARDS, exhibited the same pattern as the inflammatory cells among the five groups.

3.3. Pathological Findings after ARDS Induction. Hematoxylin and eosin staining revealed that 5 days after ARDS induction, numbers of alveolar sacs, an index of lung parenchyma integrity, was the lowest in untreated ARDS, increased progressively and significantly across the ARDS + SW, ARDS + Mito, and ARDS + SW + Mito groups, and was the highest in the SC group. Conversely, scoring of lung parenchymal crowding, an index of lung parenchymal damage, showed the opposite pattern in the five groups (Figure 4).

3.4. Inflammatory Cell Infiltration of Lung Parenchyma and DNA Damage after ARDS Induction. Immunofluorescence microscopy showed that 5 days after ARDS induction, infiltration of the lung parenchyma by CD11+ cells was significantly and progressively lower across the ARDS + SW, ARDS + Mito, and ARDS + SW + Mito groups, and was the lowest in the SC group (Figures 5 and 6). Immunofluorescence microscopy also revealed that the number of positively stained γ-H2AX cells, an indicator of DNA damage, exhibited a pattern identical to that of inflammatory cells among the five groups (Figure 7).

3.5. Histopathological Findings after ARDS Induction. Five days after ARDS induction, sections stained with Sirius oil red exhibited areas of condensed collagen deposition indicative of lung parenchymal damage with activation of fibroblasts and deposition of collagen fibers (Figure 8). Staining was the highest in specimens from untreated ARDS rats, the lowest in SC, significantly higher in the ARDS + SW and ARDS + Mito groups than in the ARDS + SW + Mito group, and significantly higher in the ARDS + SW than in
the ARDS + Mito group. Additionally, Masson’s trichrome staining revealed that in all five groups, the fibrotic areas displayed identical patterns of collagen deposition.

3.6. Oxidative Stress in Lung Parenchyma after ARDS Induction. Five days after ARDS induction, levels of NADPH oxidase- (NOX-) 1, NOX-2, and oxidized protein, three
indicators of oxidative stress, were the highest in untreated ARDS rats, were significantly and progressively reduced across the ARDS + SW, ARDS + Mito, and ARDS + SW + Mito groups, and the lowest in the SC group (Figure 9).

3.7. Biomarkers of Inflammation in Lung Parenchyma after ARDS Induction. Five days after ARDS induction, levels of matrix metalloproteinase- (MMP-) 9, tumor necrosis factor- (TNF-) α, nuclear factor- (NF-) κB, interleukin- (IL-) 1β, and intercellular adhesion molecule- (ICAM-) 1, five indices of inflammation, were the highest in untreated ARDS rats, were significantly and progressively reduced across the ARDS + SW, ARDS + Mito, and ARDS + SW + Mito groups, and the lowest in the SC group (Figure 10).

3.8. Biomarkers of Apoptosis, Fibrosis, and Mitochondrial Damage in Lung Parenchyma after ARDS Induction. Levels of cleaved caspase 3 and cleaved poly (ADP-ribose) polymerase (PARP), two indicators of apoptosis, were the highest in untreated ARDS, significantly and progressively reduced across the ARDS + SW, ARDS + Mito, and ARDS + SW + Mito groups, and the lowest in the SC groups. The same pattern was exhibited by Smad3 and transforming growth factor- (TGF-) β, two mediators of fibrosis, as well as cytosolic cytochrome c, an indicator of mitochondrial damage. Conversely, the opposite pattern was exhibited by mitochondrial cytochrome c, an indicator of mitochondrial integrity (Figure 11).

4. Discussion

In this study, we investigated the ability of SW plus mitochondrial therapy to protect the lung parenchyma from ARDS injury. Our main findings are that (1) transfused mitochondria are taken up into rat lung epithelial and parenchymal cells, (2) this effect is enhanced by SW therapy, and (3) SW plus mitochondrial therapy alleviates inflammation and ARDS damage within the lung parenchyma. Our finding that transfused, liver-derived mitochondria are taken up into lung parenchymal cells in ARDS rats is consistent with our previous study [30]. Moreover, to our knowledge, this is the first report that SW therapy enhances that effect.

Mitochondrial therapy also appears to mitigate ischemia-reperfusion injury in rat liver [26, 28]. Furthermore, we previously showed that SW therapy ameliorates ischemia-
related tissue fibrosis/ischemia-related organ damage and reduces ischemia-related organ dysfunction [34, 36, 37]. Interestingly, our histopathological findings show that ARDS-related lung fibrosis and condensed collagen deposition are greatly attenuated by SW therapy and that those beneficial effects are enhanced by mitochondrial therapy. We also observed that biomarkers of inflammation, DNA/mitochondrial damage, apoptosis, and fibrosis are all markedly elevated in ARDS animals, which is consistent with our earlier studies [30, 35]. Importantly, these parameters are all reduced by SW or mitochondrial therapy and further ameliorated by the combination of the two therapies. This extends our earlier findings [26, 28–30, 34, 36, 37] and may explain why lung injury scores (i.e., increased septal thickness and decreased number of alveolar sacs) and exude leakage from lung parenchyma are reduced in ARDS animals treated with SW plus mitochondrial therapy.

SW therapy is widely accepted for clinical application for treatment of lithotripsy [38] as well as skeletal diseases [39, 40], ischemic heart disease [41, 42], and peripheral artery disease [43, 44]. The mechanisms underlying the beneficial effects of SW therapy are thought to be related to its anti-inflammatory [32–34, 45] and angiogenic effects [32–34, 46], which enhance the healing process [47]. On the other hand, the mechanism by which SW therapy enhances transport of mitochondria into cells remains unclear. Perhaps, it induces a transient increase in cell membrane permeability, leading to increased mitochondrial uptake into the

Figure 10: Protein expressions of inflammation in lung parenchyma by day 5 after ARDS induction. (a) Protein expression of matrix metalloproteinase- (MMP-) 9, * versus other groups with different symbols (†, ‡, §, ¶), p < 0.0001. (b) Protein expression of tumor necrosis factor- (TNF-) α, * versus other groups with different symbols (†, ‡, §, ¶), p < 0.0001. (c) Protein expression of nuclear factor- (NF-) γB, * versus other groups with different symbols (†, ‡, §, ¶), p < 0.0001. (d) Protein expression of interleukin- (IL-) 1β, * versus other groups with different symbols (†, ‡, §, ¶), p < 0.0001. (e) Protein expression of intercellular adhesion molecule- (ICAM-) 1, * versus other groups with different symbols (†, ‡, §, ¶), p < 0.0001. All statistical analyses were performed by one-way ANOVA, followed by Bonferroni multiple comparison post hoc test. Symbols (*, †, ‡, §, ¶) indicate significance (at 0.05 level). SC = sham control; ARDS = acute respiratory distress syndrome; Mito = mitochondria; SW = shock wave.
cells. Consistent with that idea, previous studies showed that SW therapy increased cellular permeability, thereby facilitating delivery of genes and other molecules into cells [48, 49]. In addition, when exogenous mitochondria are taken up into cells, they often fuse and function with endogenous mitochondria (refer Figure 1). This could, at least in part, explain why SW plus mitochondrial therapy is superior to SW or mitochondrial therapy alone for protecting the lung against ARDS-induced injury.

This study has limitations. First, although the short-term outcome was promising, the long-term outcome of SW plus mitochondrial therapy for ARDS is unclear. Second, without assessment of the optimal doses of SW and mitochondrial therapy for ARDS, the relative efficacies of SW and mitochondrial therapy are uncertain.

5. Conclusions

In summary, the present study shows that SW therapy enhances uptake of mitochondria into lung epithelial and parenchymal cells and that SW-assisted mitochondrial therapy offers additional protection to the lung architecture against ARDS-induced injury.

Abbreviations

ARDS: Acute respiratory distress syndrome
BAL: Bronchoalveolar lavage
c-Casp 3: Cleaved caspase 3
c-PARP: Cleaved poly(ADP-ribose) polymerase
cyt-Cyto c: Cytosolic cytochrome c

Figure 11: Protein expressions of apoptotic, fibrotic, and mitochondrial damage biomarkers in lung parenchyma by day 5 after ARDS induction. (a) Protein expression of cleaved caspase 3 (c-Casp 3), * versus other groups with different symbols (†, ‡, §, ¶), p < 0.0001. (b) Protein expression of cleaved poly(ADP-ribose) polymerase (c-PARP), * versus other groups with different symbols (†, ‡, §, ¶), p < 0.0001. (c) Protein expression of phosphorylated (p-) Smad3, * versus other groups with different symbols (†, ‡, §, ¶), p < 0.0001. (d) Protein expression of transforming growth factor- (TGF-) β, * versus other groups with different symbols (†, ‡, §, ¶), p < 0.0001. (e) Protein expression of cytosolic cytochrome c (cyt-Cyto c), * versus other groups with different symbols (†, ‡, §, ¶), p < 0.0001. (f) Protein expression of mitochondrial cytochrome c (mit-Cyto c), * versus other groups with different symbols (†, ‡, §, ¶), p < 0.0001. All statistical analyses were performed by one-way ANOVA, followed by Bonferroni multiple comparison post hoc test. Symbols (*, †, ‡, §, ¶) indicate significance (at 0.05 level). SC = sham control; ARDS = acute respiratory distress syndrome; Mito = mitochondria; SW = shock wave.
ETC: Electron transport chain
IF: Immunofluorescent
ICAM: Intercellular adhesion molecule
IL: Interleukin
LEC: Lung epithelial cells
MMP: Matrix metalloproteinase
Mito: Mitochondria
mit-Cyto c: Mitochondrial cytochrome c
NOX: NADPH oxidase; mitochondria
NF-xB: Nuclear factor-xB
OXPHOS: Oxidative phosphorylation machinery
OCR: Oxygen consumption rate
ROS: Reactive oxygen species
SC: Sham control
SW: Shock wave therapy
TGF: Transforming growth factor.

Data Availability
The data used to support the findings of this study are available from the corresponding author upon request.

Conflicts of Interest
The authors declare that they have no conflicts of interest.

Acknowledgments
This study was supported by a program grant from Chang Gung Memorial Hospital, Chang Gung University (Grant no. CMRPG8F0611).

References
[1] G. Ailawadi, C. L. Lau, P. W. Smith et al., “Does reperfusion injury still cause significant mortality after lung transplantation?”, The Journal of Thoracic and Cardiovascular Surgery, vol. 137, no. 3, pp. 688–694, 2009.
[2] C. Brun-Buisson, C. Minelli, G. Bertolini et al., “Epidemiology and outcome of acute lung injury in European intensive care units. Results from the ALIVE study,” Intensive Care Medicine, vol. 30, no. 1, pp. 51–61, 2004.
[3] D. J. Ciesla, E. E. Moore, J. L. Johnson, J. M. Burch, C. C. Cothren, and A. S. Sauaia, “The role of the lung in postinjury multiple organ failure,” Surgery, vol. 138, no. 4, pp. 749–758, 2005.
[4] W. A. den Hengst, J. F. Gielis, J. Y. Lin, P. E. Van Schil, L. J. De Windt, and A. L. Moens, “Lung ischemia-reperfusion injury: a molecular and clinical view on a complex pathophysiological process,” American Journal of Physiology-Heart and Circulatory Physiology, vol. 299, no. 5, pp. H1283–H1299, 2010.
[5] S. M. Fiser, C. G. Tribble, S. M. Long et al., “Ischemia-reperfusion injury after lung transplantation increases risk of late bronchiolitis obliterans syndrome,” The Annals of Thoracic Surgery, vol. 73, no. 4, pp. 1041–1048, 2002.
[6] M. A. Matthy and G. A. Zimmerman, “Acute lung injury and the acute respiratory distress syndrome: four decades of inquiry into pathogenesis and rational management,” American Journal of Respiratory Cell and Molecular Biology, vol. 33, no. 4, pp. 319–327, 2005.
[7] J. Phua, J. R. Badia, N. K. J. Adhikari et al., “Has mortality from acute respiratory distress syndrome decreased over time? A systematic review,” American Journal of Respiratory and Critical Care Medicine, vol. 179, no. 3, pp. 220–227, 2009.
[8] G. D. Rubenfeld, E. Caldwell, E. Peabody et al., “Incidence and outcomes of acute lung injury,” The New England Journal of Medicine, vol. 353, no. 16, pp. 1685–1693, 2005.
[9] L. B. Ware and M. A. Matthay, “The acute respiratory distress syndrome,” The New England Journal of Medicine, vol. 342, no. 18, pp. 1334–1349, 2000.
[10] W.-I. Choi, E. Shehu, S. Y. Lim et al., “Markers of poor outcome in patients with acute hypoxemic respiratory failure,” Journal of Critical Care, vol. 29, no. 5, pp. 797–802, 2014.
[11] B. T. Thompson, R. C. Chambers, and K. D. Liu, “Acute respiratory distress syndrome,” The New England Journal of Medicine, vol. 377, no. 6, pp. 562–572, 2017.
[12] G. Bernard, “Acute lung failure — our evolving understanding of ARDS,” The New England Journal of Medicine, vol. 377, no. 6, pp. 507–509, 2017.
[13] P.-C. Li, A. Thorat, S.-C. Hsu et al., “Extracorporeal membrane oxygenation support for rituximab-induced acute respiratory distress syndrome in an ABO-incompatible living donor liver transplant recipient: successful management of a rare complication and a review of the literature,” Annals of Transplantation, vol. 22, pp. 463–467, 2017.
[14] J. J. Marini, “Advances in the support of respiratory failure: putting all the evidence together,” Critical Care, vol. 19, article S4, Supplement 3, 2015.
[15] A. S. Neto, F. D. Simonis, and M. J. Schultz, “How to ventilate patients without acute respiratory distress syndrome,” Current Opinion in Critical Care, vol. 21, no. 1, pp. 65–73, 2015.
[16] M. W. Sjoding, T. P. Hofer, I. Co, A. Courey, C. R. Cooke, and T. J. Iwashyna, “Interobserver reliability of the Berlin ARDS definition and strategies to improve the reliability of ARDS diagnosis,” Chest, vol. 153, no. 2, pp. 361–367, 2018.
[17] G. Bellani, J. G. Lafla, T. Pham et al., “Epidemiology, patterns of care, and mortality for patients with acute respiratory distress syndrome in intensive care units in 50 countries,” JAMA, vol. 315, no. 8, pp. 788–800, 2016.
[18] M. Fahr, G. Jones, H. O’Neal, J. Duchesne, and D. Tatum, “Acute respiratory distress syndrome incidence, but not mortality, has decreased nationwide: a National Trauma Data Bank study,” The American Surgeon, vol. 83, no. 4, pp. 323–331, 2017.
[19] J. Villar, D. Sulemanji, and R. M. Kacmarek, “The acute respiratory distress syndrome: incidence and mortality, has it changed?,” Current Opinion in Critical Care, vol. 20, no. 1, pp. 3–9, 2014.
[20] M. Bhargava and C. H. Wendt, “Biomarkers in acute lung injury,” Translational Research, vol. 159, no. 4, pp. 205–217, 2012.
[21] G. R. S. Budinger, G. M. Mutlu, D. Urich et al., “Epithelial cell death is an important contributor to oxidant-mediated acute lung injury,” American Journal of Respiratory and Critical Care Medicine, vol. 183, no. 8, pp. 1043–1054, 2011.
[22] T. Dolinay, Y. S. Kim, J. Howrylak et al., “Inflammasome-regulated cytokines are critical mediators of acute lung injury,” American Journal of Respiratory and Critical Care Medicine, vol. 185, no. 11, pp. 1225–1234, 2012.
[23] C.-K. Sun, C. H. Yen, Y. C. Lin et al., “Autologous transplantation of adipose-derived mesenchymal stem cells markedly

Mediators of Inflammation 15
reduced acute ischemia-reperfusion lung injury in a rodent model,” *Journal of Translational Medicine*, vol. 9, no. 1, p. 118, 2011.

[24] H. K. Yip, Y. C. Chang, C. G. Wallace et al., “Melatonin treatment improves adipose-derived mesenchymal stem cell therapy for acute lung ischemia–reperfusion injury,” *Journal of Pineal Research*, vol. 54, no. 2, pp. 207–221, 2013.

[25] M. N. Islam, S. R. Das, M. T. Emin et al., “Mitochondrial transfer from bone-marrow–derived stromal cells to pulmonary alveoli protects against acute lung injury,” *Nature Medicine*, vol. 18, no. 5, pp. 759–765, 2012.

[26] H.-C. Lin, S.-Y. Liu, H.-S. Lai, and I.-R. Lai, “Isolated mitochondria infusion mitigates ischemia-reperfusion injury of the liver in rats,” *Shock*, vol. 39, no. 3, pp. 304–310, 2013.

[27] A. Masuzawa, K. M. Black, C. A. Pacak et al., “Transplantation of autologously derived mitochondria protects the heart from ischemia-reperfusion injury,” *American Journal of Physiology-Heart and Circulatory Physiology*, vol. 304, no. 7, pp. H966–H982, 2013.

[28] H. H. Chen, Y. T. Chen, C. C. Yang et al., “Melatonin pretreatment enhances the therapeutic effects of exogenous mitochondria against hepatic ischemia–reperfusion injury in rats through suppression of mitochondrial permeability transition,” *Journal of Pineal Research*, vol. 61, no. 1, pp. 52–68, 2016.

[29] T. H. Huang, S. Y. Chung, S. Chua et al., “Effect of early administration of lower dose versus high dose of fresh mitochondria on reducing monocrotaline-induced pulmonary artery hyper- tension in rat,” *American Journal of Translational Research*, vol. 8, no. 12, pp. 5151–5168, 2016.

[30] C. K. Sun, F. Y. Lee, Y. H. Kao et al., “Systemic combined melatonin–mitochondria treatment improves acute respiratory distress syndrome in the rat,” *Journal of Pineal Research*, vol. 58, no. 2, pp. 137–150, 2015.

[31] A. Aicher, C. Heeschen, K. I. Sasaki, C. Urbich, A. M. Zeiher, and S. Dimmel, “Low-energy shock wave for enhancing recruitment of endothelial progenitor cells: a new modality to increase efficacy of cell therapy in chronic hind limb ischemia,” *Circulation*, vol. 114, no. 25, pp. 2823–2830, 2006.

[32] M. Fu, C. K. Sun, Y. C. Lin et al., “Extracorporeal shock wave therapy reverses ischemia-related left ventricular dysfunction and remodeling: molecular-cellular and functional assessment,” *PLoS One*, vol. 6, no. 9, article e24342, 2011.

[33] K.-H. Yeh, J. J. Sheu, Y. C. Lin et al., “Benefit of combined extracorporeal shock wave and bone marrow-derived endothelial progenitor cells in protection against critical limb ischemia in rats,” *Critical Care Medicine*, vol. 40, no. 1, pp. 169–177, 2012.

[34] J.-J. Sheu, H. E. E. Ali, B. C. Cheng et al., “Extracorporeal shock wave treatment attenuated left ventricular dysfunction and remodeling in mini-pig with cardiorenal syndrome,” *Oncotarget*, vol. 8, no. 33, pp. 54747–54763, 2017.

[35] F.-Y. Lee, K. H. Chen, C. G. Wallace et al., “Xenogeneic human umbilical cord-derived mesenchymal stem cells reduce mortality in rats with acute respiratory distress syndrome complicated by sepsis,” *Oncotarget*, vol. 8, no. 28, pp. 45626–45642, 2017.

[36] Y. L. Chen, K. H. Chen, T. C. Yin et al., “Extracorporeal shock wave therapy effectively prevented diabetic neuropathy,” *American Journal of Translational Research*, vol. 7, no. 12, pp. 2543–2560, 2015.

[37] C. M. Yuen, S. Y. Chung, T. H. Tsai et al., “Extracorporeal shock wave effectively attenuates brain infarct volume and improves neurological function in rat after acute ischemic stroke,” *American Journal of Translational Research*, vol. 7, no. 6, pp. 976–994, 2015.

[38] J. J. Rassweiler, C. Renner, C. Chaussey, and S. Thüröff, “Treatment of renal stones by extracorporeal shockwave lithotripsy: an update,” *European Urology*, vol. 39, no. 2, pp. 187–199, 2001.

[39] J. D. Rompe, J. Decking, C. Schoellner, and B. Nafe, “Shock wave application for chronic plantar fasciitis in running athletes: a prospective, randomized, placebo-controlled trial,” *The American Journal of Sports Medicine*, vol. 31, no. 2, pp. 268–275, 2003.

[40] L. Wang, L. Qin, H. B. Lu et al., “Extracorporeal shock wave therapy in treatment of delayed bone-tendon healing,” *The American Journal of Sports Medicine*, vol. 36, no. 2, pp. 340–347, 2008.

[41] B. Assmus, D. H. Walter, F. H. Seeger et al., “Effect of shock wave-facilitated intracoronary cell therapy on LVEF in patients with chronic heart failure: the CELLWAVE randomized clinical trial,” *JAMA*, vol. 309, no. 15, pp. 1622–1631, 2013.

[42] G. Zuozienė, A. Laucevičius, and D. Leibowitz, “Extracorporeal shockwave myocardial revascularization improves clinical symptoms and left ventricular function in patients with refractory angina,” *Coronary Artery Disease*, vol. 23, no. 1, pp. 62–67, 2012.

[43] G. Belcaro, M. R. Cesaroni, M. Dugall et al., “Effects of shock waves on microcirculation, perfusion, and pain management in critical limb ischemia,” *Angiology*, vol. 56, no. 4, pp. 403–407, 2005.

[44] F. Serizawa, K. Ito, K. Kawamura et al., “Extracorporeal shock wave therapy improves the walking ability of patients with peripheral artery disease and intermittent claudication,” *Circulation Journal*, vol. 76, no. 6, pp. 1486–1493, 2012.

[45] C. J. Wang, K. D. Yang, F. S. Wang, H. H. Chen, and J. W. Wang, “Shock wave therapy for calcific tendinitis of the shoulder: a prospective clinical study with two-year follow-up,” *The American Journal of Sports Medicine*, vol. 31, no. 3, pp. 425–430, 2003.

[46] T. H. Huang, C. K. Sun, Y. L. Chen et al., “Shock wave therapy enhances angiogenesis through VEGFR2 activation and recycling,” *Molecular Medicine*, vol. 22, no. 1, 2016.

[47] C. J. Wang, H. S. Chen, C. E. Chen, and K. D. Yang, “Treatment of nonunions of long bone fractures with shock waves,” *Clinical Orthopaedics and Related Research*, vol. 387, pp. 95–101, 2001.

[48] U. Lauer, E. Bürgelt, Z. Squire et al., “Shock wave permeabilization as a new gene transfer method,” *Gene Therapy*, vol. 4, no. 7, pp. 710–715, 1997.

[49] T. Kodama, A. G. Doukas, and M. R. Hamblin, “Shock wave-mediated molecular delivery into cells,” *Biochimica et Biophysica Acta (BBA) - Molecular Cell Research*, vol. 1542, no. 1–3, pp. 186–194, 2002.